Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 393,332,192
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • EBIT $ 17,235 M
  • EBITDA $ 18,602 M
  • 60-Month Beta 0.45
  • Price/Sales 10.43
  • Price/Cash Flow 29.07
  • Price/Book 22.11

Options Overview Details

View History
  • Implied Volatility 32.55% ( +3.35%)
  • Historical Volatility 62.20%
  • IV Percentile 53%
  • IV Rank 25.86%
  • IV High 58.88% on 12/19/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 1.48
  • Today's Volume 24,752
  • Volume Avg (30-Day) 52,909
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 398,563
  • Open Int (30-Day) 502,823

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.87
  • Number of Estimates 4
  • High Estimate 0.91
  • Low Estimate 0.85
  • Prior Year 0.71
  • Growth Rate Est. (year over year) +22.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.50 +7.55%
on 12/20/24
112.52 -22.10%
on 12/11/24
-21.55 (-19.73%)
since 12/03/24
3-Month
81.50 +7.55%
on 12/20/24
120.56 -27.30%
on 10/11/24
-27.43 (-23.84%)
since 10/03/24
52-Week
81.50 +7.55%
on 12/20/24
148.15 -40.84%
on 06/25/24
-15.97 (-15.41%)
since 01/03/24

Most Recent Stories

More News
Prediction: These 3 Healthcare Stocks Will Soar in 2025

No one knows for sure what the new year will hold for the market. However, some stocks' chances for success look particularly good.

NVO : 87.65 (+0.15%)
SMMT : 18.24 (-0.60%)
LLY : 781.98 (+0.50%)
AMGN : 261.22 (+0.75%)
Better Buy: Novo Nordisk vs. AstraZeneca

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn't know...

AZN : 66.25 (+0.56%)
NVO : 87.65 (+0.15%)
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?

Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in mid-December 2025. Pfizer also maintained its previously issued financial...

NVO : 87.65 (+0.15%)
LLY : 781.98 (+0.50%)
ABBV : 181.22 (+0.99%)
PFE : 26.59 (-0.08%)
Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

TSLA : 410.44 (+8.22%)
NVO : 87.65 (+0.15%)
LLY : 781.98 (+0.50%)
4 Top Stocks to Buy in January

Here are four stocks to buy now that could offer investors upside in the short and long terms.

MELI : 1,834.17 (+3.92%)
NVO : 87.65 (+0.15%)
AMD : 125.37 (+3.93%)
GRAB : 4.81 (+1.48%)
Should You Buy the Dip in Novo Nordisk Stock Right Now?

Shares of Novo Nordisk are in free fall following lackluster results from a new clinical trial.

NVO : 87.65 (+0.15%)
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better

Stocks soared in 2024, and 2025 could be even stronger. Let's look at key trends, government policies, and sectors poised for growth in the year ahead.

NVDA : 144.47 (+4.45%)
SOUN : 20.62 (+2.28%)
NVO : 87.65 (+0.15%)
JPM : 243.28 (+1.37%)
LLY : 781.98 (+0.50%)
AXP : 303.08 (+1.80%)
PLTR : 79.89 (+6.25%)
WMT : 90.78 (+0.87%)
Is Eli Lilly Stock a Buy, Sell, or Hold for 2025?

Eli Lilly is very close to joining the $1 trillion club. Should you buy shares now?

$SPX : 5,942.47 (+1.26%)
NVO : 87.65 (+0.15%)
LLY : 781.98 (+0.50%)
J&J Trading Near 52-Week Low: Should You Sell the Stock?

J&J’s JNJ stock closed at $145.05 on Friday, quite close to its 52-week low of $142.75. In the past three months, J&J’s stock has lost more than 10%.Slowing sales of J&J’s MedTech segment, the upcoming...

NVO : 87.65 (+0.15%)
JNJ : 144.19 (+0.12%)
LLY : 781.98 (+0.50%)
KVUE : 21.20 (-0.38%)
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?

Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move...

NVDA : 144.47 (+4.45%)
NVO : 87.65 (+0.15%)
MRK : 99.14 (-0.03%)
LLY : 781.98 (+0.50%)
NVS : 97.64 (+0.51%)
GS : 580.13 (+0.90%)
WMT : 90.78 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 88.97
2nd Resistance Point 88.58
1st Resistance Point 88.12
Last Price 87.65
1st Support Level 87.26
2nd Support Level 86.87
3rd Support Level 86.41

See More

52-Week High 148.15
Fibonacci 61.8% 122.69
Fibonacci 50% 114.82
Fibonacci 38.2% 106.96
Last Price 87.65
52-Week Low 81.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar